SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis

Rhea-AI Summary

SOPHiA GENETICS (NASDAQ: SOPH) has announced a collaboration with Agilent to enhance cancer biomarker analysis. The integration of the SOPHiA DDM™ Platform with Agilent's SureSelect Cancer Comprehensive Genomic Profiling Assay Kit will facilitate the identification of multiple biomarkers in cancer research, helping clinical labs improve efficiency and access critical data. This partnership aims to democratize data-driven medicine through advanced analytics and reporting capabilities. The collaboration is currently being tested with TomaLab, a major lab in Italy.

Positive

• Collaboration with Agilent enhances cancer biomarker analysis capabilities.
• Integration of SOPHiA DDM™ Platform with Agilent's genomic profiling tools.
• Partnership aims to democratize access to data-driven medicine.
• Streamlined process for labs to conduct in-house cancer analysis.

Negative

• None.

Collaboration provides a solution for a more in-depth analysis of cancer biomarkers

BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)-- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent to offer a comprehensive solution for cancer analysis.

Through the partnership, the SOPHiA DDM^TM Platform will be integrated with Agilent’s new Research Use Only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit. This will enable clinical researchers to accurately identify multiple biomarkers, lowering the risk of missing important information in cancer samples. The partnership brings together these two companies’ strengths in analytics and next generation sequencing (NGS) assay development to facilitate novel approaches to cancer research.

“Working with Agilent means combining best-in-class profiling practices with rich data and insights,” said Kevin Puylaert, Vice President, Business Development & Marketing, SOPHiA GENETICS. “Together, we can break traditional barriers that often limit new discoveries, democratizing access to data-driven medicine around the world.”

SOPHiA GENETICS is tailoring its analytics to work in harmony with Agilent’s target enrichment technology so that users have access to an advanced solution that allows multiple tumor markers to be detected. With the SOPHiA DDM^TM Platform, users will have an integrated solution with reporting tools that go beyond simple readouts, aligned with the information and input from the latest guidelines and clinical trials reflecting relevant biomarkers.

“We chose to partner with SOPHiA GENETICS to leverage their analytical and reporting capabilities, which complements our SureSelect Cancer CGP panel, to drive toward providing clinical researchers with a complete set of tools that will make comprehensive tumor profiling possible in their own labs,” said Kevin Meldrum, Vice President and General Manager, Integrated Genomics Division, Agilent Technologies.

The combined efforts of Agilent and SOPHiA GENETICS will make it possible for labs of varying sizes to bring cancer analysis in-house without having to send out samples or output data to other vendors and labs. This keeps impactful bioinformatic information in the hands of the user for future reference or research.

TomaLab, one of the largest research and genetics laboratories in Italy, is participating in an early-access program that is currently underway.

“Our laboratory is excited by the Agilent and SOPHiA GENETICS partnership and the release of their integrated CGP solution,” said Vittorio Grazioli, CEO of TomaLab. “Combining high-quality reagents, automation options, and powerful analytics into one unique workflow will help us maximize insights from CGP data while improving our efficiency."

About SOPHiA GENETICS

SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS Forward-Looking Statements:

This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005541/en/

Media:

Nick Puleo

npuleo@comsint.com

Source: SOPHiA GENETICS

FAQ

What is the significance of SOPHiA GENETICS' collaboration with Agilent?

The partnership aims to enhance cancer biomarker analysis, improving the accuracy of cancer research and diagnostics.

How will the integration of SOPHiA DDM™ Platform impact cancer research?

It enables clinical researchers to identify multiple biomarkers more effectively, streamlining cancer analysis processes.

Which product is involved in the SOPHiA and Agilent partnership?

The partnership involves the integration of SOPHiA's DDM™ Platform with Agilent's SureSelect Cancer Comprehensive Genomic Profiling Assay Kit.

What benefits does the SOPHiA DDM™ Platform provide to laboratories?

It allows labs to perform in-house cancer analysis efficiently, retaining important bioinformatic information and reducing reliance on external vendors.

Is there any information on early access programs for the new solution?

Yes, TomaLab in Italy is participating in an early-access program to test the integrated CGP solution.